The Pfizer Starna deal gives Pfizer three early in vivo CAR-T programmes for autoimmune diseases, for $330 million upfront. Pfizer announced the exclusive licensing agreement with Starna Therapeutics on 18 November 2026. Starna is eligible for up to $2.3 billion in development and commercial milestones. Royalties on net sales of approved products come on top. Pfizer describes all three programmes as pre-IND, so none has a US investigational new drug application yet.
The release does not name the three programmes or their targets. It also leaves several financial terms of the Pfizer Starna deal undisclosed. It gives no combined deal value, no closing conditions and no effective date. A search on 18 November 2026 found no separate Starna release on the terms.
Pfizer Starna deal terms: upfront, milestones and royalties
Pfizer will pay Starna $330 million upfront. Starna can then earn up to $2.3 billion in milestone payments. In the release’s words, these are “associated with certain development and commercial milestones”. Royalties on net sales of approved products are payable as well.
The release does not state a total. Adding the two disclosed amounts gives up to $2.63 billion, before royalties. BioSpace rounded that figure to “up to $2.6B” in its headline. The sum is a ceiling, not the price paid. Most of it depends on programmes that have not yet entered clinical development under Pfizer.
What the release leaves out
Several terms were not disclosed as at 18 November 2026. These include any near-term payments, any equity investment and the royalty rates. The release also does not split milestones between development and sales events. In addition, it names no financial or legal advisers for either party.
Deal terms at a glance
| Licensee | Pfizer Inc. (NYSE: PFE) |
| Licensor | Starna Therapeutics |
| Assets | Three unnamed pre-IND in vivo CAR-T programmes in autoimmune diseases |
| Upfront | $330 million |
| Milestones | Up to $2.3 billion (development and commercial) |
| Royalties | On net sales of approved products; rates not disclosed |
| Total announced value | Not stated (disclosed components sum to $2.63 billion) |
| Territory | Exclusive outside Greater China; Pfizer option to add Greater China |
| Closing conditions | Not disclosed |
| Announced | 18 November 2026 |
What does Pfizer get from the Starna deal?
Pfizer gets exclusive rights outside Greater China to develop, manufacture and commercialise the three programmes. It also gains rights to use Starna’s in vivo CAR-T technology in two fields. These are inflammation and immunology, and oncology. Furthermore, Pfizer holds options to exclusively license compounds from a separate research collaboration with Starna.
Territory is the main carve-out. For now, Pfizer’s rights stop at the border of Greater China. However, Pfizer holds options to expand its territory to include Greater China. The release does not say what exercising those options would cost.
The oncology field right widens the Pfizer Starna deal beyond autoimmunity. However, the three licensed programmes are all autoimmune programmes. The release does not say whether oncology programmes will follow, or on what terms.
Control sits with Pfizer outside Greater China. Pfizer will lead clinical development in that territory. It will also have “sole and exclusive control over commercialization outside of Greater China for all products”. Pfizer plans to manufacture the finished drug product for the initial clinical trials at its US facilities.
What is Starna’s in vivo CAR-T technology?
Conventional CAR-T therapy engineers a patient’s T cells outside the body, then reinfuses them. By contrast, in vivo CAR-T therapy aims to do that engineering inside the body. The approach seeks to avoid ex vivo cell manufacturing for each patient.
Pfizer describes Starna as a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Starna’s chief executive, Rongkuan Hu, Ph.D., points to its targeted lipid nanoparticle (LNP) delivery platform and RNA technology. He presents them as the foundation for its in vivo CAR-T therapies.
Endpoints News reported in October 2025 that Starna is based in Suzhou, China. It said Starna had raised a $44 million Series B. The same report described early investigator-initiated studies in lupus patients in China. Those data were preliminary and unpublished. Pfizer’s release does not refer to them.
Why the parties say they did the deal
Pfizer frames the deal as a route into a new treatment approach in autoimmunity. Michael Vincent, M.D., Ph.D., is Pfizer’s Chief Inflammation & Immunology Officer. “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases,” he said. He added that Starna’s programmes and technology give Pfizer “a powerful way to pursue these approaches.”
For Starna, Hu set out the company’s broader aim. “Our vision at Starna is to unlock the potential of RNA medicines to transform patient care,” he said. These are company statements. A search on 18 November 2026 found no clinical data from either party on the three licensed programmes.
When does the deal take effect and what happens next?
The release gives no closing conditions, effective date or antitrust filing. It does not mention a Hart-Scott-Rodino waiting period. Whether US antitrust review applies had not been stated as at 18 November 2026. Accordingly, the agreement should be read as announced, with its effective status unconfirmed.
Pfizer’s next steps are described only in general terms. It will lead clinical development outside Greater China. It also plans to make the drug product for initial trials in the United States. No timeline for an IND filing or first dosing was given.
How the Pfizer Starna deal fits the in vivo CAR-T landscape
Large pharma has moved into in vivo CAR-T through several deals since 2025. AstraZeneca completed its EsoBiotec acquisition on 20 May 2025. It paid $425 million upfront, with up to $575 million in contingent milestones. EsoBiotec’s platform uses targeted lentiviruses rather than LNPs.
On 30 June 2025, AbbVie agreed to acquire Capstan Therapeutics for up to $2.1 billion in cash. At announcement, Capstan’s lead asset, CPTX2309, was in Phase 1 for B cell-mediated autoimmune diseases. Like Starna, Capstan uses a targeted LNP approach.
Eli Lilly agreed to acquire Kelonia Therapeutics on 20 April 2026, for up to $7.00 billion in cash. That figure includes an upfront payment of $3.25 billion. At announcement, Kelonia’s lead asset, KLN-1010, was in Phase 1 for relapsed or refractory multiple myeloma. Lilly completed the acquisition in the second quarter of 2026.
The Pfizer Starna deal differs in structure. Pfizer licenses programmes rather than buying the company. It also starts with rights outside Greater China only. Pfizer has used China licensing before. On 28 May 2026 it agreed a collaboration with Innovent Biologics covering 12 oncology programmes. Pfizer paid $650 million upfront, with up to $9.85 billion in milestones.
Both Pfizer deals sit within the wider wave of China out-licensing deals in 2026. The Starna deal will be added to LSDN’s China out-licensing tracker at its next monthly update. However, direct comparisons are limited. The deals differ in stage, structure, modality and disease area. Upfront payments remain the clearest common measure.
Measured that way, the Pfizer Starna deal sits below the EsoBiotec and Kelonia upfront payments. AbbVie’s release gave a single Capstan figure of up to $2.1 billion, payable at closing. It did not split that figure into upfront and contingent parts.
What to watch next
First, watch for the programme names, targets and indications. The release discloses none of them. Second, watch for IND filings and first dosing outside China, which Pfizer will lead.
Third, watch whether Pfizer exercises its option on Greater China, and on what terms. Fourth, watch for any options exercised from the separate research collaboration. Finally, any Starna statement could clarify near-term payments and royalty rates. Until then, the Pfizer Starna deal is best read as $330 million upfront for early-stage autoimmune programmes.














